Association of Genetically Enhanced Lipoprotein Lipase–Mediated Lipolysis and Low-Density Lipoprotein Cholesterol–Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes

IMPORTANCE: Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs would require large outcome t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lotta, Luca A., Stewart, Isobel D., Sharp, Stephen J., Day, Felix R., Burgess, Stephen, Luan, Jian’an, Bowker, Nicholas, Cai, Lina, Li, Chen, Wittemans, Laura B. L., Kerrison, Nicola D., Khaw, Kay-Tee, McCarthy, Mark I., O’Rahilly, Stephen, Scott, Robert A., Savage, David B., Perry, John R. B., Langenberg, Claudia, Wareham, Nicholas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2018
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217943/
https://www.ncbi.nlm.nih.gov/pubmed/30326043
http://dx.doi.org/10.1001/jamacardio.2018.2866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217943/
https://www.ncbi.nlm.nih.gov/pubmed/30326043
http://dx.doi.org/10.1001/jamacardio.2018.2866

Ejemplares similares